;)
The Great Reversal: Redefining Cross-Border Clinical Strategy in China
For decades, clinical development leaders in US and Europe have viewed China primarily through a logistical lens: a large patient pool capable of accelerating trial enrolment. However, the industry dynamics are shifting. China has evolved from a destination for increased patient access into a source of novel biomedical innovation [Clinical Leader, 2021], [Armstrong, 2026]. Executives leading biopharmas, CROs and CDMOs must adapt to this transformation to facilitate a bi-directional flow of cross-border innovation.
From Market Destination to Innovation Engine
This evolution is evident in recent market data. Since 2015, China’s domestic innovative drug sector has matured, moving from a fast-follower model toward the development of first-in-class compounds [Engel, 2023]. Consequently, the flow of intellectual property has changed. Corporations are licensing assets from Chinese biotechs to build their global portfolios. Global sponsors are collaborating on therapies such as bispecific antibodies, antibody-drug conjugates and cell therapies, often testing them first in China before expanding into multiregional clinical trials [Pimentel, 2024].
Regulatory Harmonization and Accelerated Timelines
The bi-directional clinical activity is supported by a modernizing regulatory environment. A key milestone occurred when China’s National Medical Products Administration (NMPA) joined the International Council for Harmonisation (ICH), aligning local clinical practices with global quality standards [Vision Lifesciences, 2026]. Since then, the regulatory framework has been updated to improve development timelines. For example, China’s Clinical Trial Application process now allows a trial to proceed if the Center for Drug Evaluation (CDE) raises no objections within 30 business days of acceptance [Vision Lifesciences, 2026].
The NMPA (more specifically the CDE), has also implemented a bundled review system, allowing active pharmaceutical ingredients, excipients, and primary packaging materials to be reviewed concurrently with the marketing authorization application to reduce time to market. Furthermore, recent amendments to Chinese Patent Law offer patent term extensions of up to five years for new drugs, which brings China broadly in line with US and European frameworks and strengthens incentives for originator investment [AWA, 2026].
The Reality of On-the-Ground Execution
Securing regulatory approval for a clinical trial is only one step; executing a clinical program on the ground presents ongoing operational challenges [Huang et al., 2024]. Clinical trials in China are concentrated in urban hospitals, creating competition for resources and investigators. Foreign sponsors must navigate local governance, including where human genetic materials or data are involved, securing approval from the Human Genetic Resources Administration of China [Castañeda, 2022]. This office oversees the collection, use, and cross-border transfer of human biological samples and associated data. In practice, restrictions on sample export mean many sponsors opt to use local labs to conduct analysis within China to avoid delays and regulatory complexity. [Mitali, 2025].
Logistical hurdles also require a defined supply chain strategy. Importing clinical trial materials involves securing licenses that are valid for short timeframes. Clinical shipments require detailed documentation prior to customs clearance, and packaging must comply with local guidelines, including translated labels with specific storage instructions. While maintaining a documented cold chain is a global requirement, variability in site infrastructure and logistics networks across China makes consistent execution an ongoing operational challenge [McLaren, 2025].
Bridging the Strategic Divide
Success in this evolving landscape demands an integrated, localized strategy that treats the Chinese regulatory ecosystem not as an outlier, but as a core pillar of global development. Navigating the Chinese regulations involves a plan of action that anticipates regulatory shifts, manages multi-tiered approvals, and ensures data integrity for global review [Huang et al., 2024].
As global clinical development and operations leaders pivot from observation to active integration, the focus has shifted toward strategic synchronization between China-specific pathways and global clinical development timelines. Rather than treating China as a parallel or follow-on market, leading organizations are embedding China into early-phase development and multiregional clinical trial design. This shift enables more efficient patient recruitment, earlier data generation, and better alignment of regulatory submissions.
Ultimately, the ability to integrate China into global clinical development plans is no longer a competitive advantage, but a baseline requirement to optimize R&D pipelines, accelerate time-to-market, and maximize the commercial potential of innovative therapies in an increasingly important market [Armstrong, 2026].
References
Armstrong, A. (2026). Clinical trials are increasingly going Global—With China a main beneficiary. BioSpace. Available at: https://www.biospace.com/drug-development/clinical-trials-are-increasingly-going-global-with-china-a-main-beneficiary (Last accessed on: May 2, 2026).
Castañeda, R. (2022). The great wall: why overseas sponsors are yet to fully tap into China’s clinical trial resources. Clinical Trials Arena. Available at: https://www.clinicaltrialsarena.com/features/china-clinical-trial-challenges-cta-exclusive/?cf-view (Last accessed on: May 3, 2026).
Clinical Leader (2021). Report reflects huge growth of clinical trials in China. Available at: https://www.clinicalleader.com/doc/report-reflects-huge-growth-of-clinical-trials-in-china-0001 (Last accessed on: May 4, 2026).
Engel, M. (2023). Clinical trials in China. PharmaFocusAsia. Available at: https://www.pharmafocusasia.com/expert-corner/clinical-trials-china (Last accessed on: May 3, 2026).
Huang, H., Hou, Y., Fang, H., et al. (2024). ‘Unveiling quality of clinical trial in China: from concern to confirmation’. Cancer Communications (London), 44(5), pp. 576-579. https://doi.org/10.1002/cac2.12528.
Vision Lifesciences (2026). NMPA Drug Approval Process: Complete Guide for Global Pharma. Available at: https://visionlifesciences.com/insights/nmpa-drug-approval-process-guide (Last accessed: 7 May, 2026).
AWA (2026). Everything you need to know about China’s Patent Term Extension (PTE). https://www.awa.com/awapoint/everything-you-need-to-know-about-chinas-patent-term-extension-pte/ (Last accessed: 7 May, 2026).
McLaren, M. (2025). Clinical trial challenges in China: How a Sharp and ClinsChain pairing is breaking down barriers. Clinical Trials Arena. Available at: https://www.clinicaltrialsarena.com/sponsored/clinical-trial-challenges-china-sharp-clinschain/ (Last accessed on: May 2, 2026).
Mitali, M. (2025). Starting a clinical trial in China seems hard. Here’s what I’m learning, step by step. LinkedIn. Available at: https://www.linkedin.com/pulse/starting-clinical-trial-china-seems-hard-heres-what-im-mitali-metha-kcsff/ (Last accessed on: May 3, 2026).
Pimentel, H. (2024). Maximizing Clinical Trial Opportunities in China. Linical. Available at: https://www.linical.com/articles-research/maximizing-clinical-trial-opportunities-in-china (Last accessed on: May 3, 2026).
